Brought to you by 
Genzyme gets rights to Ceregene's Parkinson's drug
10 Jul 2007
Executive Summary
Ceregene (therapeutics for neurodegenerative disorders) licensed Genzyme exclusive worldwide marketing rights (excluding the US and Canada where Ceregene keeps rights) to its lead compound CERE120 for Parkinson's disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme gets rights to Ceregene's Parkinson's drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice